Skip Navigation


NDT Advance Access originally published online on January 23, 2006
Nephrology Dialysis Transplantation 2006 21(4):859-864; doi:10.1093/ndt/gfk054
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/4/859    most recent
gfk054v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hermann, M.
Right arrow Articles by Ruschitzka, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermann, M.
Right arrow Articles by Ruschitzka, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Review

Novel anti-inflammatory drugs in hypertension

Matthias Hermann and Frank Ruschitzka

Cardiovascular Center, Cardiology, University Hospital Zurich, Switzerland

Correspondence and offprint requests to: Matthias Hermann, Cardiovascular Center, Cardiology, University Hospital Zurich, Switzerland. Email: mhermann@gmx.de

Keywords: hypertension; inflammation; cyclooxygenase; cardiovascular risk; NSAID; coxib

The first 150 words of the full text of this article appear below.

‘Atherosclerosis is a chronic inflammatory disease induced by cholesterol ...’

Rudolf Virchow (1821–1902)

As suggested by Virchow more than a century ago, inflammation plays a pivotal role in atherogenesis and potentially also in the pathogenesis of hypertension and its sequelae. As such, the current review focuses on the role of inflammation in hypertension and emerging therapeutical approaches.



   Inflammation and cardiovascular risk
 
Clinical data
Over the last years chronic low-grade inflammation has emerged as an important new cardiovascular risk factor. Inflammatory responses within the vasculature might release pro-inflammatory cytokines that increase levels of C-reactive protein (CRP). First evidence for a role of inflammation in the development of atherosclerosis comes from studies demonstrating its prognostic value in unstable angina [1]. The inflammation hypothesis was further supported by data from observational studies demonstrating that CRP is a predictor of first cardiovascular events and might be an even stronger prognostic factor than low-density lipoprotein (LDL)-Cholesterol for coronary artery . . . [Full Text of this Article]

Experimental data


   Inflammation and endothelial function
 


   Hypertension and vascular inflammation
 


   Anti-inflammatory drugs and hypertension
 
Selective and non-selective COX-inhibitors
ACE-inhibitors and angiotensin receptor blockers
Statins
PPAR gamma activators
Cannabinoid receptor antagonist


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?